Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NouvNeu001 in Moderate-to-Advanced Parkinson's Disease
NCT07550374Phase 1Not yet recruiting
- Sponsor
- iRegene Therapeutics
- Start
- May 2026
- Primary completion
- Apr 2028
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NOUVNEU001 in Parkinson's disease (PD), sponsored by iRegene Therapeutics. Primary endpoint: Adverse Events at 48 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
NOUVNEU001
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07550374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07550374.